Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 3/20 | 0.43 |
| ▸ | CTSS | P25774 | 3/20 | 0.43 |
| ▸ | CTSK | P43235 | 3/20 | 0.43 |
| ▸ | REN | P00797 | 5/20 | 0.41 |
| ▸ | MMP1 | P03956 | 4/20 | 0.41 |
| ▸ | MMP13 | P45452 | 2/20 | 0.41 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3318363 | 0.96 | SRD5A1 (0.46) | CTSLCTSSCTSKRENMMP1 | |
| SCHEMBL3317918 | 0.94 | MMP1 (0.45) | CTSLCTSSCTSKRENMMP1 | |
| SCHEMBL3320473 | 0.93 | CTSL (0.41) | CTSLCTSSCTSKRENMMP1 | |
| SCHEMBL3323193 | 0.93 | CTSS (0.43) | CTSLCTSSCTSKRENMMP1 | |
| SCHEMBL6135862 | 0.87 | MEN1 (0.47) | CTSLCTSSCTSKMMP1MMP13 | |
| SCHEMBL3322049 | 0.87 | CYP3A4 (0.49) | CTSLCTSSCTSKSRD5A1CYP3A4 | |
| SCHEMBL3319838 | 0.85 | SRD5A1 (0.47) | CTSSMMP1MMP13SRD5A1MAPT | |
| SCHEMBL3319845 | 0.85 | SRD5A1 (0.47) | CTSSMMP1MMP13SRD5A1MAPT | |
| SCHEMBL13361605 | 0.85 | MMP1 (0.40) | CTSLCTSSCTSKRENMMP1 | |
| SCHEMBL3319635 | 0.85 | MMP1 (0.40) | CTSLCTSSCTSKRENMMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100125075-A1 | Antibacterial Agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2010-05-20 | — | — | US | disclosed |
| US-7186719-B2 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS (GB) | 2007-03-06 | — | — | US | disclosed |
| US-20050065095-A1 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2005-03-24 | — | — | US | disclosed |
| US-6846825-B1 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2005-01-25 | — | — | US | disclosed |
| EP-1202968-A2 | ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001010834-A9 | ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARM (GB) | 2001-08-09 | — | — | WO | disclosed |
| WO-2001010834-A2 | ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2001-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065095-A1 | Antibacterial agents | NQO2, DAO, Q6ZSR9 | CTSL 355/4885CTSS 760/4885CTSK 1123/4885 |
| US-20100125075-A1 | Antibacterial Agents | NQO2, DAO, Q6ZSR9 | CTSL 330/4885CTSS 749/4885CTSK 1092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.